Literature DB >> 11591903

Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir.

P A Bart1, P G Rizzardi, S Gallant, K P Golay, P Baumann, G Pantaleo, C B Eap.   

Abstract

Abacavir and amprenavir, a nucleoside reverse transcription inhibitor and a protease inhibitor, respectively, are new drugs used for the treatment of HIV. Methadone blood concentrations were measured in five addict patients receiving methadone maintenance therapy before and after introduction of abacavir plus amprenavir. The administration of these two drugs for a median period of 14 days resulted in a significant reduction (P = 0.043) of methadone concentration, with a median decrease to 35% of the original concentration (range 28-87%). Two patients reported on several occasions nausea in the morning before the intake of the daily methadone dose, which is compatible with withdrawal reaction to opioids. Because amprenavir is a cytochrome P4503A4 substrate and is involved in the metabolism of methadone, reduction of methadone concentrations could be explained by an induction of cytochrome P4503A4.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11591903     DOI: 10.1097/00007691-200110000-00010

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  15 in total

Review 1.  Drug interactions between antiretroviral drugs and comedicated agents.

Authors:  Monique M R de Maat; G Corine Ekhart; Alwin D R Huitema; Cornelis H W Koks; Jan W Mulder; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 3.  Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals.

Authors:  Dhananjay Pal; Deep Kwatra; Mukul Minocha; Durga K Paturi; Balasubrahmanyam Budda; Ashim K Mitra
Journal:  Life Sci       Date:  2010-11-01       Impact factor: 5.037

Review 4.  Methadone: applied pharmacology and use as adjunctive treatment in chronic pain.

Authors:  R Brown; C Kraus; M Fleming; S Reddy
Journal:  Postgrad Med J       Date:  2004-11       Impact factor: 2.401

5.  Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.

Authors:  E D Kharasch; P S Bedynek; A Walker; D Whittington; C Hoffer
Journal:  Clin Pharmacol Ther       Date:  2008-10       Impact factor: 6.875

Review 6.  Interindividual variability of methadone response: impact of genetic polymorphism.

Authors:  Yongfang Li; Jean-Pierre Kantelip; Pauline Gerritsen-van Schieveen; Siamak Davani
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

Review 7.  A review of the pharmacokinetics of abacavir.

Authors:  Geoffrey J Yuen; Steve Weller; Gary E Pakes
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

8.  Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment.

Authors:  Mohammad-Reza Shiran; Martin S Lennard; Mohammad-Zafar Iqbal; Oldwale Lagundoye; Nicholas Seivewright; Geoffrey T Tucker; Amin Rostami-Hodjegan
Journal:  Br J Clin Pharmacol       Date:  2009-01       Impact factor: 4.335

Review 9.  MDR- and CYP3A4-mediated drug-drug interactions.

Authors:  Dhananjay Pal; Ashim K Mitra
Journal:  J Neuroimmune Pharmacol       Date:  2006-08-02       Impact factor: 4.147

10.  Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.

Authors:  Robin Wood; Keikawus Arasteh; Hans-Jürgen Stellbrink; Eugenio Teofilo; François Raffi; Richard B Pollard; Joseph Eron; Jane Yeo; Judith Millard; Mary Beth Wire; Odin J Naderer
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.